Beyond vaccination: prognostic value of p16-HPV testing in squamous cell cervical cancer

Papers of special note have been highlighted as: • of interest

References

• 1. Wentzensen N, Arbyn M. HPV-based cervical cancer screening-facts, fiction, and misperceptions. Prev. Med. 98, 33–35 (2017).
  MedlineGoogle Scholar
• 2. Wang X, Xiumin H, Youzhong Z. Involvement of human papillomaviruses in cervical cancer. Front. Microbiol. 9, 2896 (2018).
  MedlineGoogle Scholar
• 3. Bussu F, Ragin C, Boscolo-Rizzo B. HPV as a marker for molecular characterization in head and neck oncology: looking for a standardization of clinical use and of detection method(s) in clinical practice. Head Neck 41(10), 3642–3643 (2019).
  Google Scholar
• 4. Studstill CJ, Moody CA. For better or worse: modulation of the host DNA damage response by human papillomavirus. Annu. Rev. Virol. 9, 111821–103452 (2023).
  Google Scholar
• 5. Bedard MC, Chihanga T, Carlile A et al. Single-cell transcriptomic analysis of HPV16-infected epithelium identifies a keratinocyte subpopulation implicated in cancer. Nat. Commun. 14(1), 1975 (2023).
  Medline CASGoogle Scholar
• 6. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
  MedlineGoogle Scholar
• 7. Marth C, Landoni F, Mahner S et al. ESMO Guidelines Committee. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29(Suppl. 4), iv262 (2018).
  Medline CASGoogle Scholar
• 8. Shin HI, Cho KJ, Kim MS et al. Predictive factors of distant metastasis in surgically treated HPV-positive tonsil cancer. PLOS ONE 18(3), e0283368 (2023). • The first retrospective study to examine the predictive factors for distant metastasis in surgically treated human papillomavirus (HPV)-positive tonsil cancer. It may provide insight into prognostic factors for HPV-positive squamous cell cervical cancer.
  Medline CASGoogle Scholar
• 9. Tang Y, Tong Q, Dai N et al. Evaluation of the clinical efficacy of vaginal treatment options for persistent high-risk human papillomavirus infection after excisional treatment of cervical high-grade squamous intraepithelial lesions: a systematic review and Bayesian network meta-analysis. Virol. J. 20(1), 47 (2023).
  MedlineGoogle Scholar
• 10. Huang SH, O'Sullivan B. Overview of the 8th edition TNM classification for head and neck cancer. Curr. Treat. Options Oncol. 18(7), 40 (2017).
  MedlineGoogle Scholar
• 11. Stenger M. ASCO endorses CAP guideline on HPV testing in head and neck carcinoma. Oncol. Times 40(4), 20–21 (2018).
  Google Scholar
• 12. Chaturvedi AK, Engels EA, Pfeiffer RM et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J. Clin. Oncol. 29(32), 4294–4430 (2011).
  MedlineGoogle Scholar
• 13. Russell SJ, Babiker HM, Gill BS et al. Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) and pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Cancer Immunol. Immunother. 70(6), 1655–1667 (2021). • Reports a phase I clinical trial of a new therapy in recurrent or metastatic squamous cell carcinoma of the head and neck based on HPV status. It may have implications for the use of a new therapy in HPV-induced squamous cell carcinoma of the cervix based on College of American Pathologists recommendations.
  Google Scholar
• 14. Chen Q, Huang L, Chen Y et al. FAM83A signaling induces cervical cancer cell growth and stemness via AKT/mTOR pathway. Cell Death Dis. 13(1), 32 (2022).
  MedlineGoogle Scholar
• 15. Guan M, Zhou Y, Liu C et al. The prognostic value of tumor infiltrating lymphocytes in cervical cancer: a meta-analysis. Int. J. Clin. Exp. Med. 15(2), 2673–2686 (2022).
  Google Scholar
• 16. Kim HK, Park JY, Kim HS et al. Comparison of MRI and 18F-FDG PET/CT for the detection of lymph node metastases in patients with cervical cancer. Jpn. J. Radiol. 39(12), 1207–1215 (2021).
  Google Scholar
• 17. Kwon MJ, Kim J, Hong SH et al. Discovery and validation of EGF pathway biomarkers that predict response to neoadjuvant chemotherapy in cervical cancer. Clin. Cancer Res. 27(5), 1371–1382 (2021).
  MedlineGoogle Scholar
• 18. Lim MC, Lee M, Shim SH et al. A randomized Phase II trial of axitinib versus placebo plus paclitaxel/carboplatin as first-line therapy for advanced squamous cell cervical cancer. Gynecol. Oncol. 164(1), 132–139 (2022). • This randomized clinical trial compares axitinib plus chemotherapy to placebo plus chemotherapy as first-line treatment for advanced squamous cell cervical cancer. It is relevant to your manuscript's focus on the prognostic value of cervical cancer.
  Google Scholar
• 19. Patel MM, Mavvaji S, Morosky S et al. Identification of molecular biomarkers for the prediction of treatment response in cervical cancer patients. Cancer Med. 10(3), 856–869 (2021).
  Google Scholar
• 20. Li T, Li L, Li T et al. Analysis of the survival and prognostic factors of cervical cancer in China: a hospital-based study from 2005 to 2019. BMC Cancer 21(1), 844 (2021).
  MedlineGoogle Scholar